awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q55280381-1EC45CCB-BAD0-4553-9BF3-29C6A52A3F13
Q55280381-1EC45CCB-BAD0-4553-9BF3-29C6A52A3F13
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55280381-1EC45CCB-BAD0-4553-9BF3-29C6A52A3F13
Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.
P2860
Q55280381-1EC45CCB-BAD0-4553-9BF3-29C6A52A3F13
BestRank
Statement
http://www.wikidata.org/entity/statement/Q55280381-1EC45CCB-BAD0-4553-9BF3-29C6A52A3F13
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
73df84e5e02dd599ff120fdc39850935fc8a5023
P2860
Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week res